Invest with Confidence:
- Follow TipRanks' Top Wall Street Analysts to uncover their success rate and average return.
- Join thousands of data-driven investors – Build your Smart Portfolio for personalized insights.
SAB Biotherapeutics (SABS) just unveiled an update.
The Company has announced the appointment of Mr. Conley through a press release on May 30, 2024. This information, while provided to the public, is not intended for legal liability under the Securities Exchange Act of 1934, nor is it to be included in any future securities filings unless explicitly stated.
For a thorough assessment of SABS stock, go to TipRanks’ Stock Analysis page.
